Flow cytometric analysis of Human CD86 expression on Human Peripheral Blood cells. Human Peripheral Blood cells were stained with APC Mouse Anti-Human CD14 Antibody and either Pacific Blue Rabbit IgG Isotype Control (left panel) or SDT Pacific Blue Rabbit Anti-Human CD86 Antibody (right panel) at 5 μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
Pacific Blue Rabbit Anti-Human CD86 Antibody (S-990-1)
Pacific Blue Rabbit Anti-Human CD86 Antibody (S-990-1)
Price:
Regular price
$70 USD
Regular price
Sale price
$70 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | CD86 |
| Synonyms | T-lymphocyte activation antigen CD86; Activation B7-2 antigen; B70; BU63; CTLA-4 counter-receptor B7.2; FUN-1; CD28LG2 |
| Location | Cell membrane |
| Accession | P42081 |
| Clone Number | S-990-1 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Isotype Control | S0B1550 |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | uman Peripheral Blood cells |
| Purification | Protein A |
| Concentration | 0.2 mg/ml |
| Conjugation | Pacific Blue |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.09% sodium azide |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 5μl per million cells in 100μl volume | Hu |
Background
CD86, also known as B7-2, is a co-stimulatory molecule expressed on the surface of antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells. It plays a crucial role in the immune response by interacting with CD28 on T cells to provide a necessary co-stimulatory signal for T cell activation, proliferation, and differentiation. Additionally, CD86 can also bind to CTLA-4, an inhibitory receptor on T cells, thereby regulating immune responses and maintaining immune homeostasis. This dual functionality makes CD86 a key target in immunotherapy research, particularly in the development of cancer treatments and autoimmune disease management strategies.
Picture
Picture
FC
